BOSTON--(BUSINESS WIRE)--Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, today unveiled the latest advancements in its innovative product platform. These new features, developed in collaboration with expert pathologists around the world who use the product in routine clinical practice, underscore Ibex’s commitment to creating tools that meet the needs of those on the frontline of patient care.
Ibex's accurate and robust algorithms, which are the most widely deployed AI tools in clinical pathology, have been further enhanced. By leveraging large and diverse datasets, incorporating insights from the company’s extensive international network of expert pathologists, and implementing features validated by live customers and clinical studies, the algorithms are increasingly reliable and versatile across all supported tissue types - prostate, breast and gastric - with broad capabilities identifying dozens of tissue morphologies.
Central to this release is an expanded focus on breast cancer, reflecting Ibex’s ongoing mission to bolster diagnostic confidence. The platform now includes fully automated “zero-click”, AI-enhanced HER2 immunohistochemistry (IHC) scoring, offering pathologists a powerful tool for improving accuracy and reproducibility.1 2,3 Ibex Breast HER2 automatically identifies areas of invasive cancer, detects the tumor cells within them, classifies their staining patterns and delineates HER2 expression into four standard scores: 0, 1+, 2+ and 3+, based on the 2023 ASCO/CAP guidelines.4 This enhancement automates and optimizes case review, including the highly subjective HER2-low cases. Ibex Breast HER2 is part of Ibex Breast, an integrated AI solution offering a streamlined diagnostic workflow. Pathologists can review H&E and IHC stained slides with AI support, facilitating rapid, consistent and objective diagnosis, scoring and reporting of breast biopsies and excisions.5,6,7
Recognizing the importance of seamless lab workflows, Ibex has enhanced the platform’s interoperability to include DICOM support and continues to partner with industry leaders on integrations that make it easier than ever for pathologists to incorporate the AI technology into daily practice. The latest product version boasts the Leica Image Quality certification, which recognizes inclusion of the International Color Consortium (ICC) profile and ensures the highest quality diagnostic images.
Additionally, Ibex’s newest platform ushers in enhanced capabilities for tissue and tumor length measurements and supports a wider range of tissue preparation techniques to meet the diverse needs of labs worldwide.
Finally, Ibex recently announced that its product platform received In Vitro Diagnostic Medical Devices Regulation (IVDR) certification. Together with HiTrust qualification and existing International Organization for Standardization (ISO) certificates, these achievements highlight dedication to meeting the highest regulatory, security and privacy standards, which accompany the platform’s cutting-edge performance.
Ibex Medical Analytics remains at the forefront of AI-driven pathology, continuously evolving to meet the needs of pathologists and improve patient outcomes. The company is proud to share these new advancements and looks forward to further innovating the field of pathology.
Information on the Ibex platform (previously known as Galen) will be available at the 36th European Congress of Pathology in Florence, Italy, between September 8-11th (Ibex Medical Analytics – booth number 123).
About Ibex Medical Analytics
Ibex Medical Analytics is transforming cancer diagnostics with clinical grade AI powered solutions for pathology. Empowering clinicians and supporting pathologists, Ibex is on a mission to provide accurate, timely and personalized cancer diagnosis for every patient. Ibex is the first and most widely deployed AI-powered platform in pathology. Pathologists worldwide use Ibex as part of their everyday routine to improve the accuracy of cancer diagnosis, implement comprehensive quality control measures, reduce turnaround times, and boost productivity with more efficient workflows. For additional company information, please visit https://ibex-ai.com/ and follow us on LinkedIn and Twitter.
*The Ibex platform includes solutions that are CE-IVD cleared and registered with the UK MHRA, TGA in Australia and ANVISA in Brazil. It is for Research Use Only (RUO) in the United States and pending FDA clearance. For additional details please approach Ibex.
1) Cyrta et al. ESMO Open (2024), 9; 54: 103071 |
2) Globerson et al. Cancer Research (2023) 83:P6-04-05 |
3) Krishnamurthy et al. Virchows Arch (2023) 483 (Suppl 1): S35 |
4) Wolff AC, et al. Arch Pathol Lab Med. 2023 Sep 1;147(9):993-1000 |
5) Sandbank et al. NPJ Breast Cancer (2022); 8:129 |
6) Salomon et al. Cancer Res (2023); 83(5 Suppl):P6-04-07 |
7) Broeckx et al. Virchows Arch (2023) 483 (Suppl 1): S36 |
